Phase 3 SOLO-2 trial

February 26, 2018February 26, 2018

EMA’s CHMP Recommends Lynparza as Maintenance Therapy for Platinum-sensitive Ovarian Cancer

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that Lynparza (olaparib) be approved to prevent disease progression and relapse in ovarian cancer patients who responded to platinum-based ... Read more

June 7, 2017June 7, 2017

Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer

News

Women with BRCA-mutated relapsed serous ovarian cancer who received AstraZeneca’s Lynparza (olaparib) as a maintenance therapy after responding to platinum-based chemotherapy took an average 14 months to see their disease progress, compared to 7.3 ... Read more

March 17, 2017March 17, 2017

Ovarian Cancer Patients Benefit from Lynparza Maintenance Tablets, Trial Suggests

News

Ovarian cancer patients who have an inherited BRCA mutation, and who responded to platinum-based chemotherapy, benefit from using Lynparza (olaparib) tablets as a maintenance treatment, a clinical trial suggests. The ... Read more